Holen Sie sich die Stockscreener-App
0.76
1.33%
0.01
Vorhandelsmarkt:
.76
Schlusskurs vom Vortag:
$0.75
Offen:
$0.74
24-Stunden-Volumen:
69,960
Relative Volume:
0.45
Marktkapitalisierung:
$21.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.52M
KGV:
-0.3636
EPS:
-2.09
Netto-Cashflow:
$-45.03M
1W Leistung:
+3.97%
1M Leistung:
-7.65%
6M Leistung:
-52.80%
1J Leistung:
-48.30%
1-Tages-Spanne:
$0.72
$0.78
1-Wochen-Bereich:
$0.7159
$0.787
52-Wochen-Spanne:
$0.6603
$2.57
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Vergleichen Sie NXTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.76 | 21.29M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-03-05 | Hochstufung | Truist | Hold → Buy |
| 2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
| 2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-02 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-05 | Eingeleitet | Needham | Buy |
| 2019-11-26 | Eingeleitet | BTIG Research | Buy |
| 2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
| 2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN
NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times
NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India
The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World
FDA clears IND for B7-H4-targeting ADC - BioWorld Online
NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com
NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan
NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa
NextCure Advances with New Cancer Drug Application - TipRanks
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
NextCure's NC605 Shows 90% Fracture Prevention in Breakthrough Bone Disease Study | NXTC Stock News - StockTitan
Logos Global Management LP Reduces Stake in NextCure Inc - GuruFocus.com
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation - Simply Wall St
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
National Presto Industries, Inc. (NYSE:NPK) Shares Sold by State of Alaska Department of Revenue - Defense World
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clin - WICZ
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
Intuitive Surg Inc (ISRG-Q) QuotePress Release - The Globe and Mail
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):